<- Go Home
LTR Pharma Limited
LTR Pharma Limited, a clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australia.
Market Cap
AUD 101.8M
Volume
632.2K
Cash and Equivalents
AUD 25.8M
EBITDA
-AUD 9.8M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-AUD 3.4M
Profit Margin
300.25%
52 Week High
AUD 0.81
52 Week Low
AUD 0.28
Dividend
N/A
Price / Book Value
3.79
Price / Earnings
-11.34
Price / Tangible Book Value
3.79
Enterprise Value
AUD 76.0M
Enterprise Value / EBITDA
-7.57
Operating Income
-AUD 9.8M
Return on Equity
29.27%
Return on Assets
-19.71
Cash and Short Term Investments
AUD 25.8M
Debt
N/A
Equity
AUD 26.9M
Revenue
AUD 1.1M
Unlevered FCF
-AUD 4.5M
Sector
Pharmaceuticals
Category
N/A